Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


A Double-Blind, Placebo-controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study of the Safety, Pharmacokinetics and Pharmacodynamics of (2R,6R)-Hydroxynorketamine in Healthy Volunteers


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT04711005

Organisation Name: National Institute of Mental Health (NIMH)

Overal Status: Recruiting

Start Date: January 11, 2021

Last Update: February 2, 2021

Lead Sponsor: National Institute of Mental Health (NIMH)

Brief Summary: A 6-cohort single ascending dose (SAD) study will be conducted in healthy volunteers utilizing a slow-infusion intravenous (IV) route of administration. Standard safety, pharmacokinetics (PK) and qEEG monitoring will be evaluated at all dose levels. Subsequently, a 3-cohort multiple ascending dose (MAD) study will be conducted. Doses will be administered on days 1, 4, 7, and 10. Standard safety parameters will be monitored, and PK will be evaluated at all dose levels.

Conditions:
  • Major Depressive Disorder


Total execution time in seconds: 0.15650105476379